Clinical study of the PROMETA Treatment Program for alcohol dependence at the Medical University of South Carolina (MUSC), Charleston, SC
Raymond F. Anton, MD, Hugh Myrick, MD, Alicia M. Baros, PhD, Patricia K. Latham, PhD, Patrick K. Randall, PhD, Tara M. Wright, MD, Scott H. Stewart, MD, Randy Waid, PhD, and Robert Malcolm, MD
60-subject, double-blind, placebo-controlled study
Percent days abstinent and time to first heavy drinking day as primary endpoints
Study published in the Journal of Clinical Psychopharmacology, August 2009; 29(4):334-342.
Clinical study of the PROMETA Treatment Program for methamphetamine dependent subjects at Research Across America, Dallas, TX
Harold C. Urschel III, MD, MMA; Larry L. Hanselka, PhD; Michael Baron, PhD
135-subject, double-blind, placebo-controlled study
Craving, drug use, and the correlation between the two as endpoints
Study published in the Journal of Psychopharmacology, November 25, 2009
An open-label study on the safety and clinical effectiveness of the PROMETA Treatment Program in treating methamphetamine dependence at Research Across America, Dallas, TX
Harold C. Urschel III, MD, MMA; Larry L. Hanselka, PhD; Irina Gromov, MD, PhD; Lenae White, MD; Michael Baron, PhD
50-subject open-label study
Craving, number of days abstinent as endpoints
Study published in Mayo Clinic Proceedings, October 2007;82(10):1170-1178
Clinical study of the PROMETA Treatment Program for alcohol dependence at Institute of Addiction Medicine, Philadelphia, PA
Joseph R. Volpicelli, M.D., Ph.D., Emily Loscalzo, M.S., Jenny Starosta, Ph.D., and Domenick Braccia, D.O.
120-subject, randomized, double-blind, placebo-controlled study
